Evidence map›Paper›PMID 26947200›Full record

ArticleThe Lancet. Haematology2016

Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study.

Margaret L Green, Wendy Leisenring, Hu Xie, T Christopher Mast, Yadong Cui, Brenda M Sandmaier, Mohamed L Sorror, Sonia Goyal, Sezen Özkök, Jessica Yi and 5 more

Registry-linked trialAbstract read
In one paragraph

Article in The Lancet. Haematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05789615 (Letermovir Prophylaxis for Cytomegalovirus Infection in Haploidentical Allogeneic Hematopoietic Cell Transplant Recipients), which is not on this map. Cited by 208 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
208citing papers in PubMed, 2 pooled it
23.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05789615 completednot on this mapstarted 2023, after this paper: background citation

Letermovir Prophylaxis for Cytomegalovirus Infection in Haploidentical Allogeneic Hematopoietic Cell Transplant Recipients: Single-center Real-world Data in China

TypeobservationalSponsorThe First Affiliated Hospital of Soochow UniversityRan2023 to 2025Enrolled200ConditionsCMV Infection, Hematopoietic Stem Cell TransplantationArmsLetermovir
3 · Its place in the literature

Who cites it

208 citing papers in PubMed, 2 syntheses or guidelines pooled it, 411 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Trial
  7. Trial
  8. Trial
  9. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

148 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Margaret L GreenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: mlgreen@uw.edu.
Wendy LeisenringDepartment of Biostatistics, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Hu XieClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
T Christopher MastDepartment of Pharmacoepidemiology, Merck and Co Inc, Kenilworth, NJ, USA.
Yadong CuiDepartment of Pharmacoepidemiology, Merck and Co Inc, Kenilworth, NJ, USA.
Brenda M SandmaierDepartment of Medicine, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Mohamed L SorrorDepartment of Medicine, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Sonia GoyalVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Sezen ÖzkökVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jessica YiVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Farah SahooVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Louise E KimballVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Keith R JeromeVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.
Morgan A MarksDepartment of Pharmacoepidemiology, Merck and Co Inc, Kenilworth, NJ, USA.
Michael BoeckhVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Fred Hutch Cancer Center · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USUniversity of Washington · US

Funding

VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Evan Newell · 1985 to 2026
$128.4M
Project 3: Stem Cell Allografts for Lymphoid MalignanciesP01CA078902 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SANDMAIER, BRENDA MARIE · 1999 to 2025
$46.1M
Project 3: Gene Therapy for Correction of Blood DisordersP01HL122173 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KIEM, HANS-PETER · 2015 to 2019
$12.9M
Infections in Hematopoietic Cell Transplant RecipientsK24HL093294 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BOECKH, MICHAEL J · 2009 to 2019
$1.5M
Impact of Comorbidities on Outcomes of Allogeneic TransplantationR00HL088021 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SORROR, MOHAMED · 2011 to 2013
$735k
CMV Entry-Specific Neutralizing Antibody in Primary Infection in TransplantationK23AI097234 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GREEN, MARGARET L · 2012 to 2016
$653k
Impact of Comorbidities on Outcomes of Allogeneic TransplantationK99HL088021 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SORROR, MOHAMED · 2007 to 2008
$178k
NCI NIH HHS CA18029NCI NIH HHS CA78902NCI NIH HHS P01 CA018029NCI NIH HHS P01 CA078902NHLBI NIH HHS HL088021NHLBI NIH HHS HL122173NHLBI NIH HHS K24 HL093294NHLBI NIH HHS K24HL093294NHLBI NIH HHS P01 HL122173NHLBI NIH HHS R00 HL088021NIAID NIH HHS K23 AI097234NIAID NIH HHS K23-AI097234
6 · The paper itself

Abstract

backgroundAlthough cytomegalovirus viral load is commonly used to guide pre-emptive therapy in the post-transplantation setting, few data are available correlating viraemia with clinical endpoints. We therefore investigated the association between cytomegalovirus viral load and mortality in the first year after haemopoietic stem cell transplantation.

methodsIn this retrospective cohort study, we included patients from the Fred Hutchinson Cancer Research Center, WA, USA, who received an allogeneic haemopoietic stem cell transplantation between Jan 1, 2007, and Feb 28, 2013, were cytomegalovirus seropositive or had a seropositive donor, and underwent weekly plasma cytomegalovirus monitoring by PCR through to day 100 post-transplantation. Cox proportional hazards models were used to estimate the association of cytomegalovirus viral load at different thresholds with overall mortality by 1 year post-transplantation, adjusting for the use of pre-emptive therapy and other factors such as neutropenia, and graft-versus-host disease.

findingsOf the 1037 patients initially selected for inclusion in this cohort, 87 (8%) patients were excluded because of missing cytomegalovirus testing and 24 (2%) were excluded because of their participation in cytomegalovirus prophylaxis trials. In the remaining 926 patients included in this study, the cumulative overall mortality was 30·0% (95% CI 26·9-33·0) 1 year after haemopoietic stem cell transplantation. 95 patients developed cytomegalovirus disease; death was directly attributable to cytomegalovirus disease in three (1%) of 263 patients who died in the first year after transplantation. A cytomegalovirus viral load of 250 IU/mL or greater was associated with increased risk of early (day 0-60 post-transplantation) death (adjusted hazard ratio [HR] 19·8, 95% CI 9·6-41·1). The risk was attenuated after day 60 (adjusted HR 1·8, 95% CI 1·3-2·3). Similar associations were noted for higher cytomegalovirus viral load thresholds.

interpretationCytomegalovirus viraemia is associated with an increased risk of overall mortality in the first year after haemopoietic stem cell transplantation, independent of the use of pre-emptive therapy, and with evidence of a positive dose-response relationship. These data indicate the suitability of viral load as a surrogate clinical endpoint for clinical trials for cytomegalovirus vaccines, biologics, and drugs.

fundingMerck and Co, National Institutes of Health.

Indexed as

CytomegalovirusCytomegalovirus InfectionsHematopoietic Stem Cell TransplantationNeoplasmsAdolescentAdultBlood DonorsChildChild, PreschoolCohort StudiesFemaleGraft vs Host DiseaseHumansInfantInfant, NewbornMale

Identifiers

PMID26947200
PMCPMC4914379
OpenAlexW2277663056

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.